Articles On Rhinomed (ASX:RNO)

Data analytics company Nielsen predicts that the American cannabis market will hit $US41 billion ($59.5 billion) by 2025 — a fivefold increase over 2018. While a good chunk of cannabis products are still illegal in the US, Nielsen reckons s...

Australia’s pharmaceutical industry is innovative and immensely supports economic prosperity of the nation. The constituent companies not only provide treatments to save lives but also contribute to Australian economy by undertaking busines...

Taking the cannabis market to the next level, the US is now taking a closer look at the industry’s lack of access to financial services. Forbes reported on Tuesday that a Republican-controlled Senate committee had scheduled a hearing for ne...

The below-mentioned healthcare stocks have provided significant returns in the last six months and have come up with major updates today (i.e. 15th July 2019).  Let’s take a look at these updates. Rhinomed Limited (ASX: RNO) A Melbourne-ba...

Rhinomed Ltd (ASX:RNO), a leader in airway technology and the developers of MuteTM, has informed the market that its Mute nasal stent is the fastest growing product in the nasal strip category in US based drug stores. Rhinomed is a Melbourn...

Wth the legalisation of medical cannabis in many countries like Canada, the global medical cannabis industry has boomed quite a bit in recent times. Let’s take a quick look at 20 cannabis companies trading on ASX. Cann Group Limited (ASX:...

Anti-snoring company Rhinomed (ASX: RNO) is undertaking a tough — but hopefully informative — medical study. The company announced today it would partner with Monash University to conduct a study based on the link between poor sleep and Aus...